Inside the World’s Most Expensive Pharmaceutical Market
Costs in the US have doubled for almost half of top-selling branded medicines over the past six years.
Maryam Mahdi | | Quick Read
The sky-rocketing prices of drugs in the US have been highlighted to a global audience in recent months; the price hikes of much-needed drugs, such as insulin and Humira, have become the subject of much debate. With a single vial of Humalog, a branded version of insulin, costing $274 in 2017 (1), many Americans are priced out of access.
“While high prices are of no benefit to the average citizen, they are even worse for the 12 percent of adults who fall into the category of being uninsured or underinsured. These patients pay based on the list price of the drug, and not on the “true,” post-rebate prices. As the gap widens between list and post-rebate prices, these patients pay disproportionately more,” says Nathan Wineinger, Director of Biostatistics and Assistant Professor at Scripps Research.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- NE Wineinger, Y Zhang , EJ Topol. “Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.” JAMA Netw Open. (2019).
- IQVIA, “Medicine Use and Spending in the U.S.: A Review of 2017 and Outlook to 2022.” Available at: bit.ly/2ISnzIS. Last accessed: June 28, 2019.
- Health Affairs Blog, “R&D Costs For Pharmaceutical Companies Do Not Explain Elevated US Drug Prices.” Available at:https://bit.ly/2XfNQtq. Last accessed: June 28, 2019.